Inflammatory skin diseases have large patient populations in China.According to Frost & Sullivan, there are estimated to be 6.9 million Ps patients in China by 2030, 20% to 30% of whom having moderate-to-severe disease, indicating an estimated drug market of US$9.5 billion. In the same year, there are estimated to be 81.3 million AD patients, 30% of whom having moderate-to-severe disease,indicating an estimated drug market of US$7.2 billion, and 2.1 million PN patients,with no approved biologic therapies for PN in China as of LPD, indicating a market with substantial unmet medical needs. Our pipeline consists of five drug candidates for skin diseases,namely, QX001S, an IL-12/IL-23p40 inhibitor, for Ps; QX004N, an IL-23p19 inhibitor, for the same indication; QX005N, an IL-4Rα inhibitor, for AD, PN and chronic spontaneous urticaria (CSU); QX013N, a humanized IgG1 mAb targeting c-kit, for CSU; and QX010N, an IL-31R inhibitor, for pruritus.

Inflammatory rheumatic diseases are multiple immune diseases, such as ankylosing spondylitis (AS), systemic lupus erythematosus (SLE)and lupus nephritis (LN). In addition to persistent and mysterious pain, rheumatic conditions can cause patients to develop deformities so severe that daily tasks like walking or getting dressed feel impossible. In 2030, there are estimated to be 4.0 million AS patients in China, with an estimated drug market of US$6.7 billion, and 1.1 million SLE patients, with an estimated drug market of US$4.0 billion. Our pipeline consists of two drug candidates for rheumatic diseases, namely, QX002N,targeting IL-17A, for AS and LN; and QX006N, targeting IFNAR1, for SLE.

Inflammatory respiratory diseases, such as asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic obstructive pulmonary disease (COPD), have large patient populations in China. In 2030, there are estimated to be 78.1 million asthma patients in China, about 10% of whom having severe disease, indicating an estimated drug market of US$10.7 billion. In the same year, there are estimated to be 23.1 million CRSwNP patients, with an estimated drug market of US$0.6 billion, and 110.8 million COPD patients, with an estimated drug market of US$7.4 billion. Our pipeline consists of three drug candidates for respiratory diseases, namely, QX005N, targeting IL-4R , for CRSwNP and moderate-to-severe asthma; QX008N, targeting TSLP, for asthma and moderate-to severe COPD; and QX007N, targeting IL-33, for COPD.

Inflammatory digestive diseases, such as ulcerative colitis (UC) and Crohn’s disease (CD), are conditions characterized by chronic inflammation of the gastrointestinal tract, which can be aggressive and significantly impact the patient’s quality of life. In 2030, there are estimated to be 1.2 million UC and CD patients in China, with an estimated drug market of US$5.3 billion. Our pipeline consists of two drug candidates for digestive diseases, namely, QX001S for UC/CD and QX004N for CD.